Edison healthcare quarterly: How to please some of the people some of the time
There’s just no pleasing some people. Take AstraZeneca’s investors, for instance. A $1.3bn acquisition, an innovative risk-sharing deal with the world’s biggest biotech company, Amgen, and the departure of an unpopular CEO – all within the space of four weeks – was still not enough to stem a haemorrhaging share price and prevent over £2bn being wiped off the UK company’s market
cap in a day.